Fulfilling the Promise of RNA Therapies for Cardiac Repair and Regeneration

Stem Cells Transl Med. 2023 Aug 16;12(8):527-535. doi: 10.1093/stcltm/szad038.

Abstract

The progressive appreciation that multiple types of RNAs regulate virtually all aspects of tissue function and the availability of effective tools to deliver RNAs in vivo now offers unprecedented possibilities for obtaining RNA-based therapeutics. For the heart, RNA therapies can be developed that stimulate endogenous repair after cardiac damage. Applications in this area include acute cardioprotection after ischemia or cancer chemotherapy, therapeutic angiogenesis to promote new blood vessel formation, regeneration to form new cardiac mass, and editing of mutations to cure inherited cardiac disease. While the potential of RNA therapeutics for all these conditions is exciting, the field is still in its infancy. A number of roadblocks need to be overcome for RNA therapies to become effective, in particular, related to the problem of delivering RNA medicines into the cells and targeting them specifically to the heart.

Keywords: MicroRNA; angiogenesis; cardiac regeneration; cardioprotection; gene editing; heart; lipid nanoparticles; mRNA; siRNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aptamers, Nucleotide* / therapeutic use
  • Gene Editing
  • Heart* / physiology
  • Humans
  • RNA Interference / drug effects
  • RNA, Antisense* / therapeutic use
  • RNA, Guide, CRISPR-Cas Systems* / therapeutic use
  • Regeneration

Substances

  • RNA, Antisense
  • Aptamers, Nucleotide
  • RNA, Guide, CRISPR-Cas Systems